Ivonescimab plus chemotherapy for pretreated mesothelioma
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial is testing a new immunotherapy drug (ivonescimab) combined with chemotherapy for people with mesothelioma that has already been treated. It aims to see if this combination can shrink tumors or slow the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are of Asian ethnicity and between 18 and 75 years old.
- You have been diagnosed with malignant pleural mesothelioma (a type of cancer in the lining of the lung).
- Your cancer has gotten worse after 1 or 2 prior treatments (like chemotherapy, immunotherapy, or anti-angiogenic therapy).
- You have at least one tumor that can be measured on scans.
- Your blood counts and kidney function are adequate (hemoglobin ≥90, neutrophils ≥1.5, creatinine clearance ≥50).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called ivonescimab for people with pleural mesothelioma (a cancer of the lung lining) that has grown back after earlier immunotherapy and chemotherapy. The drug may help by blocking a protein that tumors use to hide from the immune system, possibly slowing or shrinking the cancer.
This trial studies how well pembrolizumab (an immune therapy) works when added to chemotherapy before image-guided surgery for malignant pleural mesothelioma. It aims to shrink or control the cancer and improve surgical results by combining treatments.
This trial tests whether adding cadonilimab (an immune treatment) and bevacizumab (a medicine that targets blood supply to tumors) to standard chemotherapy can control pleural malignant mesothelioma that cannot be removed with surgery. It’s meant for people who have not yet started medicine for advanced disease and who meet health and blood test requirements.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with chemotherapy for people with malignant mesothelioma that cannot be treated with surgery or radiation. It may be an option whether you are starting treatment for the first time or have had up to three prior treatments.
This trial tests a combination of four medicines (two newer immune-boosting drugs, a blood vessel-blocking drug, and chemotherapy) to treat advanced mesothelioma—a serious lung cancer caused by asbestos exposure. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a new drug, cadonilimab, combined with standard chemotherapy for people with pleural mesothelioma that has come back after platinum-based treatment. The goal is to see if this combination can shrink tumors or slow the disease.
Hear when a new Pretreated Pleural Mesothelioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.